English
AR-42 (OSU-HDAC42), CAS 935881-37-1
AR-42 (OSU-HDAC42), CAS 935881-37-1
Artikelnummer
BPS27603-1
Verpackungseinheit
5 mg
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Background: AR-42 induces histone H3 acetylation, α-tubulin acetylation and p21 up-regulation, which have been considered as the hallmark indicators of HDAC inhibition. AR-42 has been found to modulate several apoptosis inhibitors as well as cell survival regulator, including Akt, Bcl-xL, Bax, Ku70 and surviving, and exert potent antitumor activity against multiple tumor types, such as human prostate and hepatic cancers, at least partially through PI3K/Akt pathway inhibition. AR-42 has been designated an orphan drug by the FDA for the treatment of meningioma and schwannoma of the central nervous system. Meningioma and schwannoma are rare, benign tumors that can present in different locations within the brain and the spinal cord and may cause substantial morbidity.
Biological Activity: AR-42 is a pan-HDAC inhibitor with IC50 of 16-30 nM. It has demonstrated greater potency and activity in solid tumors and hematological malignancies (including chronic lymphocyte leukemia, or CLL, B-cell lymphoma, prostate and ovarian cancers) when compared to vorinostat (SAHA), the first of two marketed compound in the class.
CAS Number: 935881-37-1
Description: AR-42 (also known as OSU-HDAC42), a derivative of hydroxamate-tethered phenylbutyrate is a broad-spectrum deacetylase inhibitor of both histone and non-histone proteins. AR-42 treatment induces histone hyperacetylation and p21WAF/CIP1 overexpression, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.
Purity: ≥99% by HPLC
Solubility: Soluble in DMSO
Storage Stability: Store at or below -20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.
Target: HDAC
Biosafety Level: Not applicable (BSL-1)
References: 1. Burns, S.S., et al. Cancer Res. 2013 Jan 15;73(2):792-803.
2. Zhang, S., et al. Int J Cancer. 2011 Jul 1;129(1):204-13.
3. Lucas, D.M., et al. PLoS One. 2010 Jun 3;5(6):e10941
Background: AR-42 induces histone H3 acetylation, α-tubulin acetylation and p21 up-regulation, which have been considered as the hallmark indicators of HDAC inhibition. AR-42 has been found to modulate several apoptosis inhibitors as well as cell survival regulator, including Akt, Bcl-xL, Bax, Ku70 and surviving, and exert potent antitumor activity against multiple tumor types, such as human prostate and hepatic cancers, at least partially through PI3K/Akt pathway inhibition. AR-42 has been designated an orphan drug by the FDA for the treatment of meningioma and schwannoma of the central nervous system. Meningioma and schwannoma are rare, benign tumors that can present in different locations within the brain and the spinal cord and may cause substantial morbidity.
Biological Activity: AR-42 is a pan-HDAC inhibitor with IC50 of 16-30 nM. It has demonstrated greater potency and activity in solid tumors and hematological malignancies (including chronic lymphocyte leukemia, or CLL, B-cell lymphoma, prostate and ovarian cancers) when compared to vorinostat (SAHA), the first of two marketed compound in the class.
CAS Number: 935881-37-1
Description: AR-42 (also known as OSU-HDAC42), a derivative of hydroxamate-tethered phenylbutyrate is a broad-spectrum deacetylase inhibitor of both histone and non-histone proteins. AR-42 treatment induces histone hyperacetylation and p21WAF/CIP1 overexpression, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.
Purity: ≥99% by HPLC
Solubility: Soluble in DMSO
Storage Stability: Store at or below -20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.
Target: HDAC
Biosafety Level: Not applicable (BSL-1)
References: 1. Burns, S.S., et al. Cancer Res. 2013 Jan 15;73(2):792-803.
2. Zhang, S., et al. Int J Cancer. 2011 Jul 1;129(1):204-13.
3. Lucas, D.M., et al. PLoS One. 2010 Jun 3;5(6):e10941
| Artikelnummer | BPS27603-1 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 27603-1 |
| Green Labware | Nein |
| Verpackungseinheit | 5 mg |
| Mengeneinheit | STK |
| Produktinformation (PDF) |
|
| MSDS (PDF) |
|
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
